These drugs treat opioid withdrawal and opioid-induced constipation, respectively.
These drugs treat opioid withdrawal and opioid-induced constipation, respectively.
Sleep deprivation and fatigue have far-reaching consequences in the workplace, from poor productivity to injury or death.
All workers will now have the right to file a claim for mental injuries, based upon extraordinary work-related stress incurred on the job.
A proposed bill would apply to male and female reproductive systems for firefighters and EMTs.
Private industry employers reported 2.6 million nonfatal workplace injuries and illnesses in 2023, down 8.4% from 2022.
We checked the stats and reviewed our readers’ favorite articles from RxInformer magazine to bring you a list of our most engaging content from 2024.
This drug has been approved for the treatment of multiple chronic inflammatory disorders.
128 million adults in the U.S. are affected by hypertension and cardiovascular diseases.
Recent data from CWCI and WCRI, plus clinical concerns.
As part of a legislative-mandated study on work-related PTSD, the survey could influence regulator objectives for 2025.
A recent study involving the compound DOI showed promising results in mice.
A new NCCI report found that hotter and colder temperatures were associated with higher claims frequency, as much as 10% higher in some cases.
Tirzepatide was no longer considered in shortage, removing compounding privileges, until litigation remanded the decision.
Healthes’ AVP of Information Security, Tony Brown, discusses how cyber threats affect workers’ comp organizations.
NCCI hosted a recent webinar on opioid utilization, while Fair Health published a new Opioid Tracker tool to monitor state opioid data.
WCRI reports for Delaware and Philadelphia reported increases, matching patterns seen previously in other states.
These assistants must be under the supervision of a board-authorized provider.
A new issue of RxInformer magazine, plus Leaders Speak posts in WorkCompWire, featuring Sandy Shtab and Silvia Sacalis.
The benefits of different screening strategies and therapeutic interventions.
The push comes after a letter carrier died after working without air conditioning in 95° weather.
The FDA requested additional trial data, with researchers eager to continue psychedelic trials.
High-cost claims are defined as the top 5% of medical payments within 36 months of injury.
Stop by our educational session or visit our booth for the latest issue of RxInformer magazine.
The FDA issued notices for certain migraine, acetaminophen, clonazepam, and semaglutide products.
Comorbid obesity can complicate recovery, and new drugs create new pharmacy considerations.
The U.S. Department of Labor proposed new rules, while other states introduce legislation.
Behavioral health services represented 8% of total medical payments.
Risk & Insurance magazine reviews the function and value of workers’ comp PBMs – including thoughts from Healthe leaders.
Healthe Clinical experts, Silvia Sacalis and Amanda Waltemath, will speak at the Montana Governor’s Conference on Workers’ Compensation.
Dermatologicals made up the largest share of drug payments, with NSAIDs coming in second.
What is the place of these costly medications in workers’ comp?
Approximately 741 injured workers died of opioid overdose deaths in Massachusetts.
A new bill would give providers more discretion in what medical conditions could qualify a patient for medical cannabis.
Five treatment centers would offer psychedelic therapy for veterans and former first responders.
Adjusters Assemble! Visit Healthe at Booth #921 to learn how we reduce day-to-day burdens for claims professionals.
Notable trends include a decrease in opioid utilization, generic substitution for Lyrica, and increased topical spend.
An increase in the teen workforce could impact workplace injury and claims management.
As another state considers protections, WCRI publishes new data on heat’s impact on workplace accidents.
Oklahoma and Rhode Island enact new presumptions, with Georgia adding extra coverage.
A Maryland taskforce will plan regulation, while Arizona will tentatively cover MDMA treatment for first responders with PTSD.
New data from Quest Diagnostics 2024 Drug Testing Index, and industry leaders discuss how rescheduling will impact workers’ comp.
A new naloxone nasal spray will soon be available.
Identifying and combating a multifaceted problem, including proven and developing strategies.
A total of 14 different reports examine workers’ comp system performance across 17 states from 2017-2022.
While bureaucratic wheels may take time, marijuana will become a Schedule III drug soon.
Healthe’s VP of Clinical Services, Silvia Sacalis, will co-present this educational session at PRIMA 2024.
Patients taking this muscle relaxant may be impacted by a lot from Eugia US/AuroMedics Pharma.
As firefighters see more presumptions for heart disease, keeping track of heart medications could grow in importance.
Visit Healthe at RISKWORLD® 2024 at Booth #1833 for your copy or download a copy now.
If enacted, Senate Bill 2900 would require worker protections from extreme heat and cold.
Different types of cancers are being added to pre-existing presumptions.
Pick up a copy of the new Summer 2024 edition of RxInformer magazine, and learn how Healthe is transforming healthcare.
Simlandi injection was approved for arthritic conditions, while Namzaric receives its first generic approval.
As the market grows, it becomes necessary to understand efficacy, costs, and alternatives.
Tenure more than age and other factors had a higher association with cumulative trauma claims.
California, Georgia, New York, Oklahoma, and Pennsylvania could start a national trend.
Connecticut, Missouri, and New Hampshire join 10 other states considering psychedelics bills.
Amanda Waltemath, Director of Clinical Services joins a panel discussion on April 10th, and Tate Rice, Director of Product Management speaks to Risk & Insurance.
While no clear link is established to these obesity and diabetes drugs, the FDA will continue to monitor data.
